Marco Rebolledo-Fuentes
Affiliations: | Faculty of Sciences, Department of Chemistry | University of Chile, Santiago, Región Metropolitana, Chile |
Google:
"Marco Rebolledo-Fuentes"Mean distance: (not calculated yet)
Collaborators
Sign in to add collaborator| Bruce K. Cassels | collaborator | 2001-2011 | University of Chile |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| CASTRO-CASTILLO V, GALDÁMEZ A, REBOLLEDO-FUENTES M, et al. (2012) ¹H AND 13C NMR SPECTRAL ASSIGNMENTS AND X-RAY CRYSTALLOGRAPHY OF 4,5,8,12b-TETRAHYDRO-ISOINDOLO[1,2 -α ]ISOQUINOLINE AND DERIVATIVES Journal of the Chilean Chemical Society. 57: 972-976 |
| Castro-Castillo V, Rebolledo-Fuentes M, Theoduloz C, et al. (2010) Synthesis of lakshminine and antiproliferative testing of related oxoisoaporphines. Journal of Natural Products. 73: 1951-3 |
| Quinteros-Muñoz D, Sáez-Briones P, Díaz-Véliz G, et al. (2010) Behavioral profiles in rats distinguish among "ecstasy," methamphetamine and 2,5-dimethoxy-4-iodoamphetamine: Mixed effects for "ecstasy" analogues. Behavioral Neuroscience. 124: 662-76 |
| Abin-Carriquiry JA, Urbanavicius J, Scorza C, et al. (2010) Increase in locomotor activity after acute administration of the nicotinic receptor agonist 3-bromocytisine in rats. European Journal of Pharmacology. 634: 89-94 |
| Vilches-Herrera M, Miranda-Sepúlveda J, Rebolledo-Fuentes M, et al. (2009) Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorganic & Medicinal Chemistry. 17: 2452-60 |
| CASTRO-CASTILLO V, REBOLLEDO-FUENTES M, CASSELS BK. (2009) SYNTHESIS OF A-RING-SUBSTITUTED 5,6,8,12B-TETRAHYDROISOINDOLO[1,2-A]ISOQUINOLIN-8-ONES Journal of the Chilean Chemical Society. 54 |
| Abin-Carriquiry JA, Costa G, Urbanavicius J, et al. (2008) In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: implications for Parkinson's Disease. European Journal of Pharmacology. 589: 80-4 |